Biofilm and Borrelia: Why Chronic Lyme Disease Is So Difficult to Treat
“I was treated — and I'm still sick.” I hear this sentence daily in my practice. It describes the central paradox of chronic Lyme disease: a diagnosis was made, an antibiotic therapy was carried out — and yet the symptoms persist. The key to the explanation lies deep within the bacterium itself: in the biofilm.
What is a Biofilm?
A biofilm is a protective community of microorganisms embedded in a self-produced matrix of polysaccharides, proteins, and DNA. Borrelia are capable of forming such biofilms in human tissue — particularly in joints, the nervous system, and skin.
Within this protective film, Borrelia can dramatically reduce their metabolic activity, making them practically invisible to conventional antibiotics. Antibiotics work primarily on actively growing bacteria — and bacteria in a biofilm are precisely not that.
The Core Problem
Standard antibiotic protocols for Lyme disease (usually 3–4 weeks) were developed for the fast-growing, spirochete-form Borrelia — not for biofilm-bound persistence forms.
The Three Persistence Forms of Borrelia
Borrelia burgdorferi is a survival artist. Under stress conditions — for example, antibiotic exposure — it can adopt three different survival forms:
1. Spirochete Form (Active Phase)
The classic, corkscrew-shaped form. Actively motile, responsive to doxycycline and other antibiotics. Causes the typical early symptoms (erythema migrans, fever, joint swelling).
2. L-Forms (Cell Wall-Deficient Variants)
Without their cell wall, Borrelia become insensitive to antibiotics like beta-lactams (penicillin, amoxicillin) — because these target precisely the cell wall. L-forms can survive “hidden” intracellularly in macrophages and fibroblasts.
3. Dormant Cysts (Round Bodies)
The most radical survival form: Borrelia roll into cysts, reduce their metabolism to near zero, and can remain inactive in tissue for years. They are completely resistant to most antibiotics. Under immunosuppression or other triggers, they can be reactivated.
Why Standard Tests Fail
The classic two-tier diagnostic test (ELISA + Western Blot) measures antibodies — i.e., the immune system's response to Borrelia spirochetes. The problem: Borrelia in biofilm or cysts barely stimulate the immune system. Antibody production falls, tests become negative — even though the bacteria are still present.
This mechanism explains the alarming phenomenon of “seronegative chronic Lyme disease”: the patient is sick, the test says negative. Experience in my practice shows: the patient's clinical picture must always take precedence over the laboratory value.
Modern Therapeutic Approaches Against Biofilm
Disulfiram (Antabuse)
Originally an alcohol deterrent, it shows strong efficacy against spirochetes, biofilm forms, and cysts in studies. Currently being investigated in clinical trials (Stanford University).
Dapsone Combination Therapy
Dapsone (a sulfone antibiotic) has proven effective against L-forms and cysts. In combination with doxycycline and a biofilm-breaker (e.g., stevia extract, NAC), a multi-front strategy can emerge.
Pulsed Antibiotic Protocols
Through periodic therapy breaks, dormant cysts are reactivated — and then attacked with antibiotics in the active phase. A rhythm of 4 weeks therapy / 2 weeks break has proven clinically effective.
Biofilm Breakers
Enzymes like lumbrokinase or serrapeptase can dissolve the extracellular matrix of the biofilm and make the sleeping Borrelia beneath accessible to antibiotics again.
Dr. Bottero's Conclusion
Chronic Lyme disease is neither imagined nor a post-infectious syndrome in the classical sense. It is an active infection with an exceptionally adaptable pathogen. The therapeutic goal must be to attack all three persistence forms simultaneously — with a carefully planned, individualized combination protocol. The paradigm of “2 weeks of antibiotics and done” must be overcome for these patients.
— Dr. Philippe Bottero, Specialist in Infectiology
